Jaguar Health, (JAGX) announced the results of the special meeting of Jaguar stockholders held on December 9, 2020. As previously announced, the meeting was adjourned to December 22, 2020.
The Company’s stockholders approved two proposals at the Special Meeting. On November 6, 2020, the Company filed a definitive proxy statement regarding the Special Meeting on Schedule 14A with the SEC. A free copy of Jaguar’s proxy statement and other SEC filings is available on Jaguar’s corporate website (http://www.sec.gov).
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
As revealed last week, Jaguar Health, (JAGX) finished a road show with the Swiss Development Forum, a sponsor of Post Pandemic Recovery Equity, a European special purpose acquisition firm. The Business expects to create Napo EU, a subsidiary in Europe focused on the production of crofelemer for diarrhoea associated with ‘long-hauler’ post-COVID-19 recovery patient syndrome, in order to achieve a possible merger with SPAC, which intends to invest between EUR 20 million and EUR 50 million. Napo EU will be licenced exclusively to Crofelemer for Europe, the company’s latest patented medicinal medicine, which will be needed to produce crofelemer for inflammatory diarrhoea and HIV-related diarrhoea indications.
The Swiss Development Forum is holding an investor webinar on Napo EU and SPAC on Wednesday 23 December at 10:30 AM Eastern. By clicking here, investors wanting to take part in the webinar are encouraged to participate.